NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk
20 Avril 2017 - 5:00PM
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical
company developing drug-device combinations for central nervous
system (CNS) disorders, today announced that the company’s
CEO, Oded S. Lieberman, PhD, will ring The Nasdaq Stock Market
Opening Bell in New York on Friday, April 21, 2017.
A live stream of the ceremony will be available
at http://livestream.com/nasdaq/live from
approximately 9:15 a.m. ET until 9:30 a.m. ET.
NeuroDerm will also host its first Investor Day
in New York from 10:30 a.m. to 1:30 p.m. on April 21, and will
sponsor and participate in the 23rd Parkinson’s Unity Walk in
Central Park on Saturday, April 22.
The Parkinson's Unity Walk (PUW), a grassroots
organization, began in 1994 through the dedicated efforts of
patients, families, support groups, and friends who were affected
by Parkinson's disease. Their main goal was to raise awareness and
funds for research to find a cure for Parkinson's. Over the last
twenty-two years, the Unity Walk has grown from 200 participants in
the first event to approximately 9,000 participants in the 2016
Walk. The funds raised for the Walk have also dramatically
increased with each passing year. In 1994, the Unity Walk raised
$16,000 in research funds, and in 2016 over $1,400,000 was raised
for Parkinson’s research. Donations from the Unity Walk have gone
to support research at several major U.S. Parkinson's foundations.
Additional information is available at:
http://www.unitywalk.org/.
“April is Parkinson’s disease awareness month,
and we are pleased to have multiple opportunities over the next few
days to help support the Parkinson’s community and share our
commitment to developing novel therapies that have the potential to
transform the treatment of this debilitating disease,” said Dr.
Lieberman. “The courage and determination of the Parkinson’s
patients who participate in the Unity Walk inspire everyone at
NeuroDerm to remain diligent in our efforts to complete the
clinical development of our lead product candidate, ND0612, and
prepare to submit regulatory filings for this innovative treatment
in the United States and Europe.”
About
NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing
drug-device combinations for central nervous system (CNS) disorders
that are designed to overcome major deficiencies of current
treatments and achieve enhanced clinical efficacy through
continuous, controlled administration. NeuroDerm has three product
candidates in different stages of development that offer a solution
for almost every Parkinson’s disease patient from the moderate to
the very severe stage of the disease. NeuroDerm has developed a
line of levodopa and carbidopa (LD/CD) product candidates
administered through small belt pumps that deliver a continuous,
controlled dose of LD/CD. The LD/CD product candidates are ND0612L
and ND0612H, which are used for treatment of moderate and advanced
Parkinson’s disease patients, respectively, and which are delivered
subcutaneously. In addition, NeuroDerm is developing ND0701, a
novel subcutaneously delivered apomorphine formulation for patients
who suffer from moderate to severe Parkinson’s disease and who do
not respond well to LD/CD. NeuroDerm is headquartered in the
Weizmann Science Park in Rehovot, Israel.
NeuroDerm Contact:Oded S.
Lieberman, PhD, CEOoded@neuroderm.comTel.: +972-8-946 2729 Cell:
+1-617-517 6077
U.S. Investor Contact:David
CareyLazar Partners Ltd.dcarey@lazarpartners.com+212-867-1768
NEURODERM LTD. (NASDAQ:NDRM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
NEURODERM LTD. (NASDAQ:NDRM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024